Synapse

← Global & Regional Health Technology Assessment

Papers in Global & Regional Health Technology Assessment

Page 3 · newest first

  1. Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensusGlobal & Regional Health Technology Assessment · 2021
  2. Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in ItalyGlobal & Regional Health Technology Assessment · 2021
  3. Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and TreatmentGlobal & Regional Health Technology Assessment · 2021
  4. Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in ItalyGlobal & Regional Health Technology Assessment · 2021
  5. Costs of the management of hemophilia A with inhibitors in SpainGlobal & Regional Health Technology Assessment · 2021
  6. Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospitalGlobal & Regional Health Technology Assessment · 2021
  7. Towards standardization of economic evaluation research in the youth psychosocial care sector: A broad consultation in the NetherlandsGlobal & Regional Health Technology Assessment · 2020
  8. Cost-effectiveness of adding psychomotor therapy to a multidisciplinary rehabilitation program for chronic painGlobal & Regional Health Technology Assessment · 2020
  9. Cost-effectiveness and budget impact of a lifestyle intervention to improve cardiometabolic health in patients with severe mental illnessGlobal & Regional Health Technology Assessment · 2020
  10. Budget Impact Analysis of anakinra in the treatment of patients with Still’s DiseaseGlobal & Regional Health Technology Assessment · 2020
  11. Patterns of prescription, hospitalizations and costs of herpes zoster in patients at risk, from a large Italian claims databaseGlobal & Regional Health Technology Assessment · 2020
  12. Cost-effectiveness analysis of dupilumab for the treatment of severe atopic dermatitis in adults in ItalyGlobal & Regional Health Technology Assessment · 2020
  13. Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia BGlobal & Regional Health Technology Assessment · 2020
  14. Valorization of clinical trials from the Italian National Health Service perspective: definition and first application of a model to estimate avoided costsGlobal & Regional Health Technology Assessment · 2020
  15. Value-based healthcare: Il nuovo approccio di AIFA alla determinazione multidimensionale del valoreGlobal & Regional Health Technology Assessment · 2020
  16. A cost-minimization analysis of a preventive testing strategy for relatives of patients with BRCA mutated ovarian cancerGlobal & Regional Health Technology Assessment · 2020
  17. Economic Evaluation of Family-Based Therapies for Children and Adolescents: what do we know?SHILAP Revista de lepidopterología · 2019
  18. HTA nei processi assistenziali e nei modelli organizzativiGlobal & Regional Health Technology Assessment · 2019
  19. Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysisGlobal & Regional Health Technology Assessment · 2019
  20. The offset effect of pharmaceutical innovation: A review studySHILAP Revista de lepidopterología · 2019
  21. The economic impact of biosimilars in Italy: a scenario analysisSHILAP Revista de lepidopterología · 2019
  22. Monitoring treatment response in metastasic colorectal cancer: Economic evaluation of PrediCTC versus computed tomography scanSHILAP Revista de lepidopterología · 2019
  23. The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in ItalyGlobal & Regional Health Technology Assessment · 2019
  24. Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in ItalySHILAP Revista de lepidopterología · 2019
  25. The offset effect of pharmaceutical innovation: A review studyGlobal & Regional Health Technology Assessment · 2019
  26. Monitoring treatment response in metastasic colorectal cancer: Economic evaluation of PrediCTC versus computed tomography scanGlobal & Regional Health Technology Assessment · 2019
  27. Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in ItalyGlobal & Regional Health Technology Assessment · 2019
  28. The economic impact of biosimilars in Italy: a scenario analysisGlobal & Regional Health Technology Assessment · 2019
  29. The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in ItalyGlobal & Regional Health Technology Assessment · 2019
  30. Twenty Years of Hepatitis C in the Treviso District (Local Health Unit 2): Treatments, Clinical Management and Cost AnalysisGlobal & Regional Health Technology Assessment · 2019
  31. Determining the value contribution of emicizumab (Hemlibra ® ) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysisGlobal & Regional Health Technology Assessment · 2019
  32. Cost-description and multiple imputation of missing values: the SATisfaction and adherence to COPD treatment (SAT) studySHILAP Revista de lepidopterología · 2018
  33. Epidemiology and economic impact of moderate and severe neurotrophic keratopathy in ItalyGlobal & Regional Health Technology Assessment · 2018
  34. The hospitalization burden of influenza: just the tip of the iceberg?SHILAP Revista de lepidopterología · 2018
  35. Assessing social and economic impact of subcutaneous mAbs in oncologySHILAP Revista de lepidopterología · 2018
  36. Economic burden of disease of uncontrolled acromegalic patients: the acromegaly Italian collaborative study groupSHILAP Revista de lepidopterología · 2018
  37. Thromboprophylaxis in Patients with Atrial Fibrillation: A Real Practice AnalysisSHILAP Revista de lepidopterología · 2018
  38. The hospitalization burden of influenza: just the tip of the iceberg?Global & Regional Health Technology Assessment · 2018
  39. Cost-description and multiple imputation of missing values: theSATisfaction and adherence to COPD treatment(SAT) studyGlobal & Regional Health Technology Assessment · 2018
  40. Assessing social and economic impact of subcutaneous mAbs in oncologyGlobal & Regional Health Technology Assessment · 2018
  41. Il trattamento con farmaci intravitreali anti-VEGF in pazienti naïve in ItaliaGlobal & Regional Health Technology Assessment · 2018
  42. Epidemiology and economic impact of moderate and severe neurotrophic keratopathy in ItalyGlobal & Regional Health Technology Assessment · 2018
  43. Cost-Effectiveness of Azacitidine Compared with Low-Doses of Chemotherapy (LDC) in Myelodysplastic Syndrome (MDS)SHILAP Revista de lepidopterología · 2017
  44. Mortality Cost of Duchenne Muscular DystrophySHILAP Revista de lepidopterología · 2017
  45. Intravitreal corticosteroids for the treatment of macular edema: review and assessment of quality of the evidenceSHILAP Revista de lepidopterología · 2017
  46. Mortality Cost of Duchenne Muscular DystrophySHILAP Revista de lepidopterología · 2017
  47. Cost-Effectiveness of Azacitidine Compared with Low-Doses of Chemotherapy (LDC) in Myelodysplastic Syndrome (MDS)Global & Regional Health Technology Assessment · 2017
  48. Analysis of Productivity Costs in Cancer: A Systematic ReviewGlobal & Regional Health Technology Assessment · 2017
  49. Economic Evaluation of Family-Based Therapies for Children and Adolescents: what do we know?Global & Regional Health Technology Assessment · 2017
  50. Rapid Reviews with Health-Technology Assessments in Reimbursement Systems – an Examination of Ireland as a Case StudyGlobal & Regional Health Technology Assessment · 2016